secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001641172-25-025257
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026
--------------------------------------------------------------------------------

- Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.
- Notes mature Feb 19, 2026; convertible at 80% of lowest closing price in prior 5 trading days.
- Proceeds to pay off debt and for working capital; RBW Capital Partners received 8% commission.
- Registration rights agreement requires resale registration statement filed by Sept 18, 2025.
- Company may prepay at 20% premium; conversion capped at 4.99% (or 9.99%) beneficial ownership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225025257/0001641172-25-025257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000164117225025257/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer